Harmonising Outcome Measures for Eczema
University of Nottingham
  • Print

HOME Publications


HOME Consensus Statements

Spuls PI, Gerbens LA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, Prinsen CA, von Kobyletzki LB, Singh JA, Williams HC, Schmitt J; HOME initiative collaborators.  POEM a core instrument to measure symptoms in clinical trials: a HOME statement.  Br J Dermatol. 2016 Nov 17. doi:10.1111\bjd.15179 [Epub ahead of print]

Schmitt J, Spuls PI, thomas KS, Simpson E, Furue M, Deckert S, Dohil M, Apfelbacher C, Singh JA, Chalmers J, Williams HC; HOME initiative collaborators. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014 Oct;134(4):800-7. doi: 10.1016/j.jaci.2014.07.043


HOME Roadmap

Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M, Chalmers J, Williams HC. The Harmonising Outcomes for Eczema (HOME) roadmap: A methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol 2015 Jan;135(1):24-30. doi: 10.1038/jid.2014.320. Epub 2014 Sep 4


HOME Delphi Exercise

Schmitt J, Langan S, Stamm T and Williams HC, on behalf of the Harmonizing Outcome Measurements in Eczema (HOME) Delphi panel. Core outcome domains for controlled trials and clinical recordkeeping in eczema: International multiperspective Delphi consensus process. J Invest Dermatol (2011) 131, 623-630; doi: 10.1038/jid.2010.303 Epub 2010 Oct 14


HOME Meetings

Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2016 Jul 19. doi: 10.1111/bjd. 14773. [Epub ahead of print]

JR Chalmers, J Schmitt, C Apfelbacher, M Dohil, L F Eichenfield, EL Simpson et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema / dermatitis clinical trials (HOME). Br J Dermatol 2014 Jul 1. doi: 10.1111/bjd.13237 [Epub ahead of print]

Schmitt J et al, Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012: Sep;67(9):1111-1117; doi 10.1111/j.1398-9995.2012.02874.x.  Epub 2012 Jul 30

Schmitt J, Williams H on behalf of the HOME Development Group, Harmonising Outcome Measures for Eczema (HOME). Report from the first international consensus meeting (HOME I) 24 July 2010, Munich, Germany. Br J Dermatol 2010: 163; 1166-1168


Systematic Reviews

Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, Nankervis H, Svensson A, Terwee CB, Zhang J, Apfelbacher CJ, Spuls PI, Harmonising Outcomes Measures for Eczema (HOME) initiative. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.  Allergy 2017 Jan;72(1):146-163. doi: 10.1111/all.12959, Epub 2016 Jul 13.

Barbarot S, Rogers NK, Abuabara K, Aubert H, Chalmers J, Flohr C, Hanifin J, Naldi L, Margolis DJ, Paul C, Ridd MJ, Anna Schuttelaar ML, Simpson E, Tauber M, Volke A, Weidinger S, Wilkes SR, Wollenberg A, Thomas KS. Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. J Am Acad Dermatol 2016 Nov; 75(5):1038-1044. doi: 10.1016\jaad.2016.05.043. Epub 2016 Aug 10.

Heinl D, Prinsen CA, Sach T, Drucker AM, Ofenloch R, Flohr C, Apfelbacher C. Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review. Br J Dermatol. 2016 Aug 20 doi: 10.1111/bjd.14966 [Epub ahead of print]. 

Gerbens LAA, Chalmers JR, Rogers NK, Nankervis H, Spuls PI, on behalf of the Harmonising Outcome Measures for Eczema (HOME) Initiative.  Reporting of symptoms in randomised controlled trials of atopic eczema treatments: a systematic review. Br J Dermatol. 25 Mar 2016 doi: 10.1111/bjd.14588 [Epub ahead of print].

Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2015 Dec 11. pii: S0190-9622(15)02284-7. doi: 10.1016/j.jaad.2015.09.062 [Epub ahead of print]

Heinl D, Chalmers J, Nankervis H, Apfelbacher CJ. Eczema trials: quality of life instruments used and their relation to patient-reported outcomes: a systematic review. Acta Derm Venereol. 2015 Dec 17. doi: 10.2340/00015555-2322 [Epub ahead of print].

Heinl D, Prinson CA, Deckert S, Chalmers JR, Drucker AM, Ofenloch R, Humphreys R, Sach T, Chamlin SL, Schmitt J, Apfelbacher C. Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy 2015 Nov 13. doi: 10.1111/all.12806 [Epub ahead of print].

Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P, on behalf of the Harmonising Outcome Measures for Atopic Dermatitis (HOME) initiative. Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation. J Allergy Clin Immunol 2013 Dec;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008. Epub 2013 Sep 12

Schmitt J, Langan S, Williams HC and the European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007 Dec;120(6):1389-98. Epub 2007 Oct 1

Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003 Jun;120(6):932-41

Charman C and Williams HC. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000; 136:763-769



Apfelbacher CJ, Heinl D, Prinsen CA, Deckert S, Chalmers J, Ofenloch R, Humphreys R, Sach T, Chamlin S, Schmitt J. Measurement properties of adult quality-of-life measurement instruments for eczema: protocol for a systematic review. Syst Rev. 2015 Apr 16;4(1):48


Other relevant publications

Zhao CY, Hao EY, Oh DD, Daniel BS, Martin LK, Su JC, Rodrigues M, Murrell DF.  A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate to dark-skinned patients. Br J Dermatol 2017 Apr;176(4):985-992. doi: 10.1111\bjd.15271.Epub 2017 Mar 1.

von Kobyletzki LB, Thomas KS, Schmitt J, Chalmers JR, Deckert S, Aoki V, Weisshaar E, Oja JA, Svensson A.  What factors are important to patients when  assessing treatment response: An international cross-sectional survey. Acta Derm Venereol 2017 Jan 4;97(1):86-90. doi: 10.2340/00015555-2480.

Fedorowicz Z, van Zuuren EJ. Eczema symptoms scores: are we getting closer to HOME? Br J Dermatol 2016 Oct;175(4):667-8 doi: 10.1111/bjd.14786

Gaunt DM, Metcalfe C, Ridd M. The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference. Allergy 2016 May 27. doi: 10.1111/all.12942 [Epub ahead of print]

Zhao CY, Tran AQT, Lazo-Dizon JP, Kim J, Daniel BS, Venugopal SS, Rhodes LM, Law MG, Murrell DF. A pilot comparison study of four clinician-rated atopic dermatitis severity scales. Br J Dermatol 2015 Aug;173(2):488-97. doi: 10.1111/bjd.13846. Epub  2015 Jul 1

Zhao CY, Wijayanti A, Doria MC, Harris AG, Jain SV, Legaspi KN, Dlova NC, Law MG, Murrell DF. The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: a grey area. Int J of Women's Dermatology 1 (2015) 150-154 doi.org/10.1016/j.ijwd.2015.02.002

Chalmers J, Deckert S, Schmitt J: Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative Executive Board. Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema. Curr Opin Allergy Clin Immunol. 2015 Jun;15(3):227-33. doi: 10.1097/ACI.0000000000000158.

Schmitt J. Trials are meaningful for clinical decision making only when their endpoints are valid and comparable. Br J Dermatol 2015 May;172(5):1175-7. doi: 10.1111/bjd.13806

Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis - an interpretability study. Br J Dermatol. 2015 May;172(5):1353-7. doi: 10.1111/bjd.13662. Epub 2015 Apr 16.

Thomas KS, Stuart B, O'Leary CJ, Schmitt J, Paul C, Williams HC, Langan S. Validation of treatment escalation as a definition of atopic eczema flares. PLoS One 2015 Apr 21;10(4):e0124770. doi: 10.1371/journal.pone.0124770. eCollection 2015

Smith V, Clarke M, Williamson P, Gargon E.(2014). Survey of new 2007 and 2011 Cochrane reviews found 37% of prespecified outcomes not reported. J Clin Epidemiol. 2014 Nov 18. pii: S0895-4356(14)00398-9. doi: 10.1016/j.jclinepi.2014.09.022. [Epub ahead of print]

Keener AB, (2014). Group seeks standardization for what clinical trials must measure. Nat med 2014 Aug;20(8):798-9. doi: 10.1038/nm0814-798

Gargon E, Gurung B, medley N, Altman DG, Blazeby JM, Clarke M, Williamson PR. Choosing important health outcomes for comparative effectiveness research: A systematic review. PLoS One 2014 Jun 16;9(6):e99111. doi: 10.1371/journal.pone.0099111. eCollection 2014

Langan SM, Schmitt J, Williams HC, Smith S, thomas KS. How are eczema "flares" defined? A systematic review and recommendation for future studies. Br J Dermatol 2014 Mar;170(3):548-56. doi: 10.1111/bjd.12747

Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, Sprangers MA, Blazeby JM. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials 2014 Feb 5;15:49. doi: 10.1186/1745-6215-15-49

Kirkham JJ, Boers M, Tugwell P, Clarke M, Williamson PR. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials 2013 Oct 9;14:324. doi: 10.1186/1745-6215-14-324

Basra MKA, Gada V, Ungaro S, Finlay AY, Salek SM. Infants' Dermatitis Quality of Life Index (IDQoL): A decade of experience of validations and clinical application. Br J Dermatol 2013 Oct;169(4):760-8. doi: 10.1111/bjd.12563

Kirkham JJ, Gargon E, Clarke M, Williamson PR. Can a core outcome set improve the quality of systematic reviews? A survey of the Co-ordinating Editors of the Cochrane Review Groups. Trials 2013 Jan 22;14:21. doi: 10.1186/1745-6215-14-21

Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials - issues to consider. Trials 2012 Aug 6;13:132. doi: 10.1186/1745-6215-13-132

Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012 Jan; 67(1):99-106. doi: 10.1111/j1398-9995.2011.02719.x.

Valburg RW, Williamson MG, Dirven-Meijer PC, Oranje AP, Van der Wouden JC, Moed H. Quality of life measurement and the relationship to disease severity in children with atopic dermatitis in general practice. Acta Derm Venereol 2011 Mar;91(2):147-51. doi: 10.2340/00015555-1026

Flohr C (2011) Atopic dermatitis diagnostic criteria and outcome measures for clinical trials: Still a mess. J Invest Dermatol 2011 Mar;131(3):557-9. doi: 10.1038/jid.2010.36

Charman CR, Venn AJ, Williams H. Measuring atopic eczema severity visually: Which variables are the most important to patients?  Arch Dermatol. 2005;141:1146-1151


HOME - Harmonising Outcome Measures for Eczema

Centre of Evidence Based Dermatology
University of Nottingham
King's Meadow Campus
Lenton Lane, Nottingham

Telephone: +44 115 8232435
Fax: +44 115 8468618
Email: HOME@nottingham.ac.uk